

Specimen ID: Control ID:

Phone:

Rte:

մորինների ինկիրերիկրուկինինի ինչինինինին

Patient Details

DOB:

Age(y/m/d): SSN: Gender: Patient ID:

Specimen Details

Date collected: Date received: Date entered: Date reported:

Physician Details

Ordering: Referring: ID: NPI:

General Comments & Additional Information

Reason for testing: Collectors Name: Collectors Phone #: MRO Name from CCF:

Clinical Info: Clinical Info: Clinical Info:

Ordered Items

Chain-of-Custody Protocol: Synthetic Cannabinoids Scr Lir: PSC Specimen Collection

| TESTS | RESULT | FLAG | UNITS | REFERENCE | INTERVAL | LAB |
|--|-----------|------|-------|-----------|----------|-----|
| Chain-of-Custody Protoc | 01 | | | | | |
| | Performed | | | | | 01 |
| Synthetic Cannabinoids, Synthetic Cannabinoid N | | | | | | |
| | Negative | | | | | 02 |
| Qualitative synthe metabolites of the | | | | | | |

AB-CHMINACA, AB-FUBINACA, AB-PINACA, F-AB-PINACA, ADBICA, 5F-ADBICA, ADB-PINACA, 5F-ADB-PINACA, AKB-48, 5C1-AKB-48, 5F-AKB-48, AM2201, BB-22, BB-22 hydroxyquinolines, JWH-018, JWH-073, JWH-122 JWH-250, MAB-CHMINACA, MAM-2201, PB-22, PB-22 hydroxyquinolines, 5F-PB-22, 5F-PB-22-hydroxyguinolines, UR-144, XLR-11

1.0 ng/mL Screening threshold: Analysis performed by Liquid Chromatography with Tandem Mass Spectrometry (LC/MS/MS).

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

FINAL REPORT

Page 1 of 1

